Congratulations again Sandra on leading this programme of work. Fantastic achievement.

We believe identifying the cell of origin of Squamous Cell Cancer and its extraordinary capabilities will help us focus on preventative strategies against this cancer.

Thanks to Peter Campbell, Moritz Pryzbilla and Sanger team, Thanks to Ben Simons and Ignacio Bordeu. And thanks to the L4L team, @ucl.ac.uk and @uclh.bsky.social @uclhresearch.bsky.social @cruk-cityoflondon.bsky.social and @ukri.org for their support

Subpopulations of basal cells preferentially expand, leading to loss of differentiated luminal cells, and mutant cell clonal expansions. Mutant basal cell clones migrate and repopulate whole bronchial trees where they eventually produce squamous cell lesions @sangerinstitute.bsky.social

Sandra's paper is out in Science! So pleased. Thank you to all the authors, contributors and patients that have been with us on this journey. @science.org @sandra-gl.bsky.social Aberrant basal cell clonal dynamics shape early lung carcinogenesis
www.science.org/doi/full/10....

While progress has been made in treating #NSCLC, patients would further benefit from earlier detection & effective interception. Here, Spira and colleagues explore advances in identifying premalignant lesions, and devise approaches for stratification + interventions.

https://bit.ly/3QE86...

Thanks to everyone of the SUMMIT workers, the fellows, the UCL Trails unit, the incredible UCLH trial delivery team, admin team, nurses, radiologists, radiographers, trial practitioners, our partner hospitals and PIs and the incredible management team at the hospital and university that enabled this

207 (79·3%) of 261 individuals with prevalent screen-detected lung cancer were diagnosed at stage I or II and surgical resection was the primary treatment modality in 201 (77·0%) of 261 individuals.
Amazing achievement delivered through a pandemic by @ucl.ac.uk @uclh.bsky.social funded by GRAIL Inc

12 773 participants were recruited and analysed. 261 (2·0%) of 12 773 participants were diagnosed with lung cancer (including 163 [1·3%] participants with screen-detected lung cancer and 98 [0·8%] with delayed screen-detected lung cancer [ie, after a 3-month or 6-month nodule follow-up CT]).

Congratulation to the SUMMIT team on our publication in Lancet Oncology today: Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study.
authors.elsevier.com/sd/article/S...